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desmin causes disruption of the extrasarcomeric desmin 
cytoskeleton and extensive mitochondrial abnormalities 
regarding subcellular distribution, number and shape. At 
the molecular level, we uncovered changes in the abun-
dancy and assembly of the respiratory chain complexes and 
supercomplexes. In addition, we revealed a marked reduc-
tion of mtDNA- and nuclear DNA-encoded mitochondrial 
proteins in parallel with large-scale deletions in mtDNA 
and reduced mtDNA copy numbers. Hence, our data dem-
onstrate that the expression of mutant desmin causes multi-
level damage of mitochondria already in early stages of 
desminopathies.
Keywords Desminopathy · R350P desmin · R349P desmin 
knock-in · Desmin knock-out · Intermediate filament · 
Myofibrillar myopathy · Protein aggregate myopathy · 
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Abstract Secondary mitochondrial dysfunction is a fea-
ture in a wide variety of human protein aggregate diseases 
caused by mutations in different proteins, both in the cen-
tral nervous system and in striated muscle. The functional 
relationship between the expression of a mutated protein 
and mitochondrial dysfunction is largely unknown. In par-
ticular, the mechanism how this dysfunction drives the dis-
ease process is still elusive. To address this issue for pro-
tein aggregate myopathies, we performed a comprehensive, 
multi-level analysis of mitochondrial pathology in skeletal 
muscles of human patients with mutations in the intermedi-
ate filament protein desmin and in muscles of hetero- and 
homozygous knock-in mice carrying the R349P desmin 
mutation. We demonstrate that the expression of mutant 
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Introduction
The term “desminopathies” stands for a group of familial 
and sporadic myopathies and cardiomyopathies [15] that 
are caused by mutations in the human desmin (DES) gene 
on chromosome 2q35, which encodes the muscle-specific 
intermediate filament protein desmin [42]. Desminopathies 
belong to the expanding group of protein aggregate myopa-
thies (PAMs) and are currently classified as a subgroup of 
myofibrillar myopathies (MFMs) [66]. The latter comprise 
a genetically and clinically heterogeneous group of striated 
muscle diseases that share the morphological characteris-
tics of desmin-positive protein aggregates and degenerative 
changes of the myofibrillar apparatus. MFMs are caused by 
mutations in genes coding for structural components of the 
myofibrillar apparatus (filamin-C, myotilin, ZASP, FHL1, 
titin), the extrasarcomeric cytoskeleton (desmin, plectin), 
and components with functions in protein quality control 
(DNAJB6, BAG-3, αB-crystallin) [66].
Since the first description of human desmin mutations 
in 1998 [29], more than 70 myopathy- or cardiomyopathy-
causing desmin mutations have been reported [15]. The 
vast majority of desminopathies follows an autosomal-
dominant trait of inheritance. The few autosomal-recessive 
cases may be subdivided in cases with maintained expres-
sion of mutant desmin [2, 9, 29, 56, 60] and others with a 
complete lack of desmin [7, 23, 31, 51]. While the former 
resulted in myopathies and cardiomyopathies with desmin-
positive protein aggregates, the latter were not reported to 
display aggregation pathology. Human desminopathies are 
clinically highly variable with disease onsets ranging from 
the first to the eighth decade of life and may manifest with 
either pure skeletal muscle or cardiac disease symptoms, or 
with a combination of both [15]. To date, curative treatment 
is neither available for desminopathies nor other forms of 
PAMs.
How do human desmin mutations inflict progressive 
striated muscle damage? The intermediate filament protein 
desmin is the major component of the three-dimensional 
extrasarcomeric cytoskeleton and exerts multiple roles in 
the alignment and anchorage of myofibrils, the positioning 
of mitochondria and myonuclei, mechanosensing, stress 
endurance, and cell signaling [15]. Since muscle biopsies 
from desminopathy patients represent only late stages 
of the disease and are only available in small amounts, 
patient-mimicking disease models are required to decipher 
the sequential steps of the in vivo molecular pathogen-
esis. We recently reported the generation and characteri-
zation of R349P (c.1045_1047delAGG>insCCC) desmin 
knock-in mice, which harbor the orthologue of the most 
frequently occurring human desmin missense mutation 
R350P (c.1049G>C) [16]. These mice display age-depend-
ent skeletal muscle weakness, dilated cardiomyopathy, 
and cardiac arrhythmias and conduction defects. On the 
molecular level, the point-mutated desmin led to aberrant 
subcellular localization and increased turnover of desmin 
and its binding partners. We further demonstrated that the 
progressive muscle pathology is primarily caused by dis-
ruption of the extrasarcomeric intermediate filament net-
work rather than by the presence of pathological protein 
aggregates [16].
Several previous studies on muscle biopsy specimens 
from human desminopathies and other forms of MFMs 
reported on mitochondrial pathology [15, 24, 33, 34, 50, 
67, 68]. Moreover, various mitochondrial abnormalities 
were described in a transgenic mouse model expressing 
p.L345P mutant desmin [38] and in desmin knock-out mice 
[15, 40, 41, 44, 54, 55, 73]. In this study, we investigated 
the relationship between mutant desmin and mitochondrial 
pathology by comprehensive and multi-level analyses in 
human and murine desminopathies.
Materials and methods
R349P desmin knock‑in and desmin knock‑out mice
In this study we used the following desminopathy mouse models: 
hetero- and homozygous R349P (c.1045_1047delAGG>insCCC) 
desmin knock-in mice B6J.129Sv-Destm1.1Ccrs (http://www.
informatics.jax.org/allele/MGI:5708562; synonym: B6J.129Sv-
Destm1(R349P)Cscl&Rfsr) [16] as well as desmin knock-out mice 
B6J.129S2/Sv-Destm1Cba (http://www.informatics.jax.org/allele/
MGI:2159584) [40]. Breeding pairs of the latter were received 
by courtesy from Denise Paulin, Université Pierre et Marie Curie, 
Paris, France. The mice were handled in accordance with the 
German Animal Welfare Act (Tierschutzgesetz) as well as the 
German Regulation for the protection of animals used for experi-
mental purposes or other scientific purposes (Tierschutz-Versuch-
stierverordnung), and the investigations were approved by the 
responsible governmental animal care and use office [Landesamt 
für Natur, Umwelt und Verbraucherschutz North Rhine-West-
phalia (LANUV NRW), Recklinghausen, Germany; reference 
numbers 84-02.04.2014.A262 and 84-02.05.40.14.057].
Human skeletal muscle biopsy material
Tissue samples derived from diagnostic vastus lateralis 
muscle biopsies of two patients from a previously reported 
family with a heterozygous c.1049G>C (R350P) desmin 
mutation [3] and of one previously reported patient har-
boring the heterozygous c.735G>C desmin mutation lead-
ing to the expression of two mutant desmin protein spe-
cies (E245D and D214_E245del) [14] were obtained from 
the Department of Neurology, University Hospital Berg-
mannsheil, Ruhr-University, Bochum, Germany and the 
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Department of Neurology, University Hospital Bonn, Ger-
many, respectively. Human desmin reference sequences: 
NM_001927.3; P17661.
Antibodies
Both wild-type and R350P/R349P mutant desmin pro-
teins were detected by two commercially available desmin 
antibodies [mouse monoclonal antibody (mAb), D1033, 
Sigma-Aldrich (St. Louis, MO, USA), 1:1000 in TBS-T 
for western blotting; rabbit polyclonal antibodies (pAb), 
#10570, Progen Biotechnik GmbH (Heidelberg, Ger-
many), 1:100 in PBS for immunofluorescence], GAPDH 
by a mouse mAb [G9295, Sigma-Aldrich (St. Louis, MO, 
USA), 1:10,000 in TBS-T for western blotting], multiple 
complex I subunits by a rabbit anti-serum ([8], antibody 
#55, purified bovine complex I was used for immuniza-
tion, 1:10,000 in TBS-T for western blotting), complex II 
(SDHA) by a mouse mAb (#459200, Invitrogen, 1:1000 in 
TBS-T for western blotting), complex III [UQCRC2 subu-
nit (Core protein II)] by a mouse mAb (A11143, Molecular 
Probes, 1:3000 in TBS-T for western blotting), complex 
IV (CoxVIa subunit) by a rabbit anti-serum ([30], anti-
body #90, 1:10,000 in TBS-T for western blotting), com-
plex IV (CoxI subunit) by a mouse mAb (#59600, Invitro-
gen, 1:100 in PBS for immunofluorescence), complex V 
(ATP5A subunit) by a mouse mAb (#459240, Invitrogen, 
1:1000 in TBS-T for western blotting), and multiple subu-
nits of complexes I–V by a ready-to-use mixture of mouse 
mAbs (MS604, MitoSciences, 1:5000 in TBS-T for west-
ern blotting).
Preparation of skeletal muscle cryosections, 
histochemistry, and immunofluorescence stains
Skeletal muscle specimens were collected and immedi-
ately frozen in liquid nitrogen-cooled isopentane. Cry-
ostat sections of 5 µm thickness were placed on micro-
scope slides and air-dried for 30 min. Histochemistry 
was performed using routine staining protocols [22], 
and images were captured using an Olympus CX41 light 
microscope (Olympus, Hamburg, Germany). For immu-
nofluorescence analyses, cryosections were fixed for 
5 min with acetone, air-dried for 30 min, and permea-
bilized with PBS containing 0.2 % Triton X-100 for 15 
min. Non-specific binding was blocked with 10 % fetal 
calf serum, 1 % goat serum and 0.1 % sodium azide in 
PBS for 1 h at room temperature. Incubation with pri-
mary antibodies diluted in PBS with 3 % BSA was done 
overnight at 4 °C or for 1 h at room temperature. After 
washing, sections were incubated with appropriate goat 
anti-mouse or anti-rabbit Alexa Fluor 488, 633, and 647 
antibodies (1:200, Molecular Probes/Life Technologies 
GmbH, Darmstadt, Germany), and finally washed 
with PBS and mounted in Mowiol for analysis using a 
Leica TCS SP5/AOBS/tandem scanning system (Leica 
Microsystems GmbH, Wetzlar, Germany) with emission 
detection in sequential mode equipped with the Leica 
LAS-AF software (v. 2.7.3.9723).
Preparation of isolated skeletal muscle fibers 
and immunofluorescence analysis
Preparation of single soleus muscle fibers was performed 
as described [64]. Mice were anesthetized with isoflurane 
(Abbot) and heart-perfused with 2 % paraformaldehyde 
(PFA) in PBS by cutting off the right and punctuating the 
left heart ventricle. Subsequently, soleus muscles were dis-
sected and fixed for 15 min in 2 % PFA in PBS, followed 
by washing with PBS. After removing remaining tendons, 
muscles were cut into two halves and divided into 5–7 por-
tions, depending on the size of the muscle. The bundles 
of muscle were teased into single fibers using 90° angled, 
fine-tipped needles (Carl Reiner GmbH, Vienna, Austria), 
mounted on coated glass slides (Superfrost Plus, Thermo 
Scientific), air-dried and stored at −80 °C.
For immunofluorescence analyses, isolated fibers were 
thawed at room temperature for 15 min, encircled with a 
hydrophobic pen, and permeabilized in 0.1 % Triton X-100 
in PBS for 30 min. To reduce background signal caused 
by endogenous mouse immunoglobulins, the Mouse on 
Mouse (M.O.M.) Basic Kit (Vector Laboratories) was 
used according to the manufacturer’s instructions. 200 μl 
of “M.O.M. Diluent” were applied for 5 min, followed by 
1 h incubation with primary antibodies (mouse monoclo-
nal anti-CoxI subunit and rabbit polyclonal anti-desmin) 
diluted in “M.O.M. Diluent”. After 10 min incubation 
with 200 μl “M.O.M. Biotinylated Anti-Mouse IgG Rea-
gent” diluted 1:250 in “M.O.M. Diluent” per slide, slides 
were washed twice and secondary antibodies-dilution, 
which contained Streptavidin Protein-DyLight 550 con-
jugate (Thermo Fischer Scientific) and goat anti-rabbit 
Alexa Fluor 488 (Life Technologies), was added for 1 h at 
room temperature. After a short washing with PBS, sam-
ples were air-dried and mounted in Mowiol. Images were 
recorded using a LSM780 fluorescence laser scanning 
microscope (Carl Zeiss, Jena, Germany) equipped with a 
Plan-Apochromat 63 × 1.4NA objective lens. Images were 
obtained using the LSM780 module and the Zeiss ZEN 
software.
Ultrastructural analysis
For transmission electron microscopy, skeletal muscle spec-
imens were fixed in freshly prepared 4 % formaldehyde, 15 
% saturated picric acid and 0.5 % glutaraldehyde in 0.1 M 
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phosphate buffer pH 7.4 overnight at 4 °C, postfixed in 0.5 
% osmium tetroxide, washed and counterstained with ura-
nyl acetate, dehydrated in graded ethanol concentrations, 
and embedded in epoxy resin. Ultra-thin sections were pre-
pared (Ultracut S; Leica, Germany) and examined with a 
LEO 906E or LEO 910 transmission electron microscope 
(Carl Zeiss GmbH, Oberkochen, Germany).
Citrate synthase activity
Snap-frozen soleus muscles were pulverized in a mortar in 
liquid nitrogen and small amounts were dissolved in 300 µl 
PBS, sonicated in short time-intervals on ice, and centri-
fuged at 16,000×g for 5 min at 4 °C. Protein concentra-
tion was determined using a fluorometric dye (ProStain, 
Active Motif, Carlsbad, CA, USA) as well as densitometry 
analysis of Coomassie Brilliant Blue stained SDS gels both 
before and after adjustment of a total protein concentration 
of 0.4 mg/ml.
Citrate synthase activity was determined following the 
reduction of 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB) 
by CoA-SH liberated by the citrate synthase reaction in 
the presence of oxaloacetate and acetyl-CoA as described 
previously [39, 76]. For this assay, samples were diluted 
1:2 to 1:6 in 0.1 M Tris-HCl pH 7.0 and 80 µl samples 
were added to 920 µl incubation mix [720 µl H2O, 100 µl 
0.1 mM DNTB (Sigma, D8130; in 1 M Tris-HCl pH 8.1), 
25 µl 10 % Triton X-100, 50 µl 10 mM oxalacetate (Sigma, 
O-4126; in 0.1 M triethanolamine-HCl pH 8.0 with 5 mM 
EDTA), 25 µl 12.2 mM acetyl-CoA (Sigma, A-2181)] in a 
plastic cuvette. The linear absorbance at 412 nm was moni-
tored for 200 s in a U-2000 spectrophotometer (Hitachi).
Respiratory complex I and IV activities
Samples of snap-frozen muscle tissue were homogenized 
in 0.1 M phosphate buffer pH 7.4 (25 mg tissue per 1 ml 
buffer) three times for 15 s at 24,000 rpm with an Ultra-
Turrax homogenizer (IKA, Staufen, Germany) and centri-
fuged at 16,000×g for 15 min at 4 °C. The supernatants 
contained all cytosolic (99–100 % of lactic dehydrogenase; 
six independent control biopsy samples) and all mitochon-
drial matrix enzymes (90–95 % of citrate synthase; six 
independent control biopsy samples). The pellets, which 
contained all mitochondrial inner membrane associated 
enzyme activities (99–100 % of cytochrome c oxidase and 
NADH:CoQ1 reductase; six independent control biopsy 
samples), were re-suspended in half of the volume of the 
initially added phosphate buffer. Supernatants were kept 
snap-frozen in liquid nitrogen until use; pellet fractions 
were immediately used for the measurements.
The activity of rotenone-sensitive NADH:CoQ 1 oxi-
doreductase (complex I) was measured at 30 °C using a 
dual-wavelength spectrophotometer (Aminco DW 2000, 
SLM Instruments, Rochester, NY, USA) at 340/380 nm 
(εred-ox = 5.5 mM−1 cm−1). The reaction medium con-
tained 50 mM KCl, 1 mM EDTA, 10 mM Tris-HCl 
pH 7.4, 1 mM KCN, 100 µM CoQ1, and 150 µM NADH. 
The assay was initiated by addition of the sample and the 
velocity of NADH oxidation was monitored. To determine 
the rotenone-insensitive NADH oxidation rate, 20 µM 
rotenone was added to the assay mixture after 2 min. The 
shown activities are differences between the total NADH 
oxidation rate and the rotenone-insensitive NADH oxida-
tion rate. The cytochrome c oxidase (complex IV) activi-
ties were measured at 30 °C in 0.1 M potassium phosphate 
buffer (pH 7.4) containing 0.02 % laurylmaltoside (Sigma, 
Munich, Germany) monitoring the oxidation of ferrocy-
tochrome c in its β-band at the wavelength pair 510/535 nm 
(εred-ox = 5.9 mM−1 cm−1). To obtain reduced cytochrome 
c, oxidized bovine heart cytochrome c (purity 99 %, Sigma, 
Munich, Germany) was reduced with ascorbate, desalted 
on a Sephadex-G25 column, and stored in liquid nitrogen 
until use.
SDS‑PAGE of samples from skeletal muscle tissue
For quantitative immunoblotting extraction of proteins 
from skeletal muscle tissue was done according to [13]. 
Small amounts of snap-frozen tissue were pulverized in a 
mortar in the presence of liquid nitrogen, taken up in lysis 
buffer (5 mM Tris-HCl pH 6.8, 10 % SDS, 0.2 M DTT, 
1 mM EDTA) and heated at 95 °C for 5 min. Subsequently, 
the lysates were sonicated six times for 10 s, again heated 
for 5 min at 95 °C, and centrifuged at 16,000×g for 5 min. 
Protein concentrations of the supernatants were determined 
using a fluorometric dye (ProStain, Active Motif, Carlsbad, 
CA, USA), adjusted to 3 mg/ml by addition of lysis buffer, 
again quantitated, and finally adjusted to 1 mg/ml by addi-
tion of 1× SDS sample buffer (25 mM Tris-HCl pH 6.8, 
0.8 % SDS, 2 % 2-mercaptoethanol, 4 % glycerol, 0.001 % 
bromophenol blue). Samples were boiled once more before 
application to a SDS-polyacrylamide gel electrophoresis 
and run under standard conditions. For detection of pro-
teins, both Coomassie Brilliant Blue staining and immuno-
blotting employing appropriate antibodies were used.
Quantitative mass spectrometric analyses of soleus 
muscle lysates
Soleus muscle lysates adjusted to 1 mg/ml total protein 
in SDS sample buffer (prepared as described above) were 
used for label-free quantitative mass spectrometric analy-
ses. For fractionation, 20 µg of protein per lane were loaded 
onto 4–12 % Bis-Tris gels (NUPAGE; Life technologies). 
Gels were fixed, stained with Coomassie Brilliant Blue 
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G250 (Serva) as described in [78], and each lane was cut 
into eight fractions. The gel pieces were destained and pro-
teins digested according to [62].
Liquid chromatography/mass spectrometry (LC/MS) was 
performed on a Q Exactive Plus (Thermo Scientific) coupled 
to an ultra-high performance Dionex Ultimate 3000 liquid 
chromatography unit (Thermo Scientific) via a Nanospray 
Flex Ion-Source (Thermo Scientific, Dreieich, Germany) 
essentially as described [62] with the following exceptions: 
peptides were separated on an in-house packed 2.4 µm Repro-
sil C18 resin (Dr. Maisch GmbH, Ammerbuch-Entringen 
Germany) picotip emitter tip (diameter 100 µm, 15 cm long, 
New Objectives) using a gradient from mobile phase A (4 % 
acetonitrile, 0.1 % formic acid) to 44 % mobile phase B (80 
% acetonitrile, 0.1 % formic acid) for 30 min with a flow rate 
of 500 nl/min. The Full MS scan range was 300–2000 m/z 
with resolution of 70,000 at m/z 200. MS data were analyzed 
by MaxQuant 1.5.2.8 [19], which includes the MaxLFQ algo-
rithm [18] for reliable, label-free protein quantitation. The 
enzyme specificity was set to trypsin, missed cleavages were 
limited to 2, variable modifications were N-terminal acetyla-
tion, oxidation of methionine, deamidation on asparagine and 
glutamine, and fixed modification was carbamidomethylation 
of cysteines. The mouse reference proteome database (down-
load from Uniprot, June, 26th, 2015, 28,560 entries) was used 
to identify peptides and proteins. False discovery rate (FDR) 
for protein and peptides was 5 %.
Quantitative mass spectrometric analyses 
of microdissected type I muscle fibers
Type I fibers in murine muscle were detected via immu-
nofluorescence staining. Briefly, 10 μm cryosections were 
incubated with a primary antibody directed against myosin 
heavy chain I (NCL-MHCs Leica Microsystems, Wetzlar, 
Germany) in 1:40 dilution in PBS for 1 h at room tem-
perature (RT) followed by an incubation with a second-
ary antibody conjugated with Texas Red (goat anti-mouse 
IgG antibody, Dianova, Hamburg, Germany, 1:400 in PBS) 
for 45 min at RT. Isolation of type I muscle fibers of the 
lower extremities was performed via laser microdissec-
tion. A total area of 250,000 μm2 of type I fibers was col-
lected for each sample into tubes with 40 µl formic acid 
via laser microdissection (LMD6500, Leica Microsystems, 
Wetzlar, Germany). Samples were incubated for 30 min 
at RT, sonicated (35 kHz) for 5 min (RK31, BANDELIN 
electronic, Berlin, Germany) and centrifuged for 10 min 
(12,000×g, 4 °C). Prior tryptic digestion, the formic acid 
was removed by vacuum vaporization (rotational-vacuum-
concentrator RVC2-25CD plus, Martin Christ GmbH, 
Osterode am Harz, Germany) and the collected tissue mate-
rial was diluted in 50 mM ammonium bicarbonate (pH 7.8) 
to a final volume of 74.25 μl. Samples were reduced for 
20 min at 56 °C by addition of DTT (final concentration of 
6.7 mM) followed by alkylation with iodoacetamide (final 
concentration of 20 mM) for 15 min in the dark at RT. The 
pH was adjusted to 7.4 before adding 1 μl of 1 % Trypsin 
Enhancer ProteaseMAX Surfactant (Promega, Mannheim, 
Germany) in 50 mM ammonium bicarbonate (pH 7.8). 
Digestion was done by addition of trypsin (Serva Electro-
phoresis GmbH, Heidelberg, Germany) solution (1 μg/μl 
in 50 mM acetic acid) and overnight incubation at 37 °C. 
Digestion was stopped by addition of 4 μl of 2 % TFA, the 
samples were centrifuged for 30 min (16,000×g, 4 °C), and 
63 µl of the supernatant were transferred into a new tube. 
15 µl were used for each mass spectrometric analysis.
Label-free quantitative mass spectrometric analyses of 
tryptically digested microdissected type I muscle fibers 
was performed on an UltiMate 3000 RSLC nano LC sys-
tem (Thermo Scientific, Bremen, Germany) as recently 
described [47]. The HPLC system was online-coupled to 
the nano ESI source of a Q Exactive mass spectrometer 
(Thermo Scientific, Bremen, Germany). The ESI-MS/MS 
analysis was performed as described [11].
Raw files were analyzed using Proteome Discoverer 
(ver. 1.4.1.14) (Thermo Fisher Scientific, Rockford, IL, 
USA). Peptide identification was performed by Mascot 
(version 2.5, Matrixscience, London UK) using the mus 
musculus complete proteome downloaded from UniProt 
(release 2015_5, containing 44,467 entries + decoys). Mass 
tolerance was set to 5 ppm for precursor ions and 20 mmu 
for fragment ions. As variable chemical modifications oxi-
dation of methionine, phosphorylation of serine, threonine 
and tyrosine was used, carbamidomethylation of cysteine 
was set as fixed modification. One tryptic mis-cleavage was 
considered in the analysis. Confidence of peptide identifi-
cation was determined using a protein inference algorithm 
(PIA) [74]. The filter cut-off for the identified peptides was 
set to targeted false discovery rates of <1 %.
Ion intensity-based label-free quantification was per-
formed using Progenesis LC-MS software (Nonlinear 
Dynamics Ltd., Newcastle upon Tyne, UK) for data analy-
sis. Raw files were imported and aligned. Quantified fea-
tures were subsequently matched to peptide and protein 
identification by importing the search results from all 
samples generated using Mascot and PIA. Proteins quanti-
fied with an ANOVA p value <0.05 were considered to be 
significantly differentially expressed in one of the sample 
types.
Quantitation of mitochondrial complexes 
and supercomplexes
Liquid nitrogen snap-frozen soleus muscles were homog-
enized in 200 µl homogenization buffer (50 mM sucrose, 
20 mM sodium phosphate buffer pH 7.5, 1 mM EDTA, 
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2 mM 6-aminohexanoic acid) using an Ultra-Turrax (IKA, 
Staufen, Germany). The resulting suspension was diluted to 
a concentration of 10 mg tissue per 1 ml buffer and homog-
enized by 40 strokes of a motor-driven tightly fitting glass/
Teflon Potter-Elvehjem homogenizer. Homogenates were 
centrifuged for 10 min at 10,000×g. Pellets corresponding 
to 10 mg muscle tissue containing nuclei as well as mito-
chondrial and other membranes were resuspended in 70 µl 
of buffer A (50 mM NaCl, 50 mM imidazole, pH 7, 1 mM 
EDTA, 2 mM 6-aminohexanoic acid), solubilized by addi-
tion of 8 µl 20 % digitonin (w/v in water), centrifuged for 
10 min at 22,000×g, and the protein content of the super-
natants were determined by Lowry’s assay [45]. Equal 
amounts of proteins per lane (10 µg for immunoblots, 30 µg 
for Coomassie Brilliant Blue and enzyme activity stained 
native gels) were loaded onto 3–16 % gradient gels follow-
ing blue native electrophoresis (BNE) according to [78]. 
For quantitation of mitochondrial complexes, BN gels were 
either stained with Coomassie Brilliant Blue, blotted onto 
PVDF membranes for immunodetection, or used for an in 
gel complex I activity stain described by [81] with modifi-
cations according to [80].
mtDNA long‑range PCR
Total DNA was extracted from skeletal muscle speci-
mens by column purification as described in the manual 
of QIAamp DNA Mini Kit (QIAGEN N.V., Venlo, Neth-
erlands). Each sample was eluted twice in 200 µl elution 
buffer provided with the kit and was stored without freez-
ing at 4 °C. To detect large-scale mtDNA deletions, long-
range PCR analysis was performed in human and murine 
samples. Primer pair musMT2482F24 (5′-GTTCAAC-
GATTAAAGTCCTACGTG-3′) and musMT1005R24 
(5′-CCAGTATGCTTACCTTGTTACGAC-3′) was used 
for the murine and primer pair MT3137F26 (5′-GAGA-
AATAAGGCCTACTTCACAAAGC-3′) and MT45R22 
(5′-TGGAGAGCTCCCGTGAGTGGTT-3′) for the 
human samples (first number, 5′ nucleotide of primer; 
F, forward primer; R, reverse primer; second number, 
length of primer). PCRs were performed with the LA 
Taq Hot Start DNA polymerase (Takara Bio Inc., Otsu, 
Japan) under the following conditions for the murine/
human samples: 95 °C for 2.5 min, 10 cycles of 92 °C for 
20 s and 66.8/68 °C for 5:30 min, 20 cycles of 92 °C for 
25 s and 66.8/68 °C for 5:30 min, and 72 °C for 10 min.
mtDNA deletion quantitation
Using total DNA prepared as described above, two dif-
ferent single molecule PCRs (smPCR) were performed 
for quantitative evaluation of the mtDNA deletions in 
murine samples. The first primer pair musMT2482F24 
and musMT1005R24 amplified almost the entire mtDNA 
and the second primer pair musMT15795F21 (5′-TTCT-
TACTTCAGGGCCATCAA-3′) and musMT1005R24 a 
shorter region within the minor arc. The latter region of the 
mtDNA usually does not contain deletions and was used to 
determine the total amount of mtDNA molecules. For each 
genotype, the amount of large-scale mtDNA deletions was 
calculated according to [83] by dividing the quotient of 
the number of positive bands to its single molecule dilu-
tion in the deletion PCR with the quotient of the number 
of positive bands to its single molecule dilution in the 
total mtDNA amount PCR. Both PCRs were performed 
with LA Taq Hot Start DNA polymerase (Takara Bio Inc., 
Otsu, Japan) under the following conditions for the long/
short mtDNA fragments: 95 °C for 2.5 min, 10 cycles of 
92 °C for 20 s and 66.8/55 °C for 5:30/3 min, 20 cycles of 
92 °C for 25 s and 66.8/55 °C for 5:30/3 min, and 72 °C for 
10 min.
mtDNA copy number
The mtDNA copy number was evaluated by quantita-
tive real-time PCR (qPCR) using total DNA prepared as 
described above. For the detection of qPCR products, 2× 
SYBR Green qPCR Master Mix (Biotool, Munich, Ger-
many) was used. The qPCR was performed with two differ-
ent concentrations of the DNA sample, 10 and 20 ng/μl, in 
triplicates for each dilution. Primers amplifying the human 
mitochondrial fragment were MT3922F25 (5′-GAAC-
TAGTCTCAGGCTTCAACATCG-3′) and MT4036R26 
(5 ′-CTAGGAAGATTGTAGTGGTGAGGGTG-3 ′) ; 
primers for KCNJ10 (KIR4.1, potassium voltage-gated 
channel subfamily J member 10) were KIR835F19 
(5′-GCGCAAAAGCCTCCTCATT-3′) and KIR903R19 
(5′-CCTTCCTTGGTTTGGTGGG-3′). Primers amplifying 
the murine mitochondrial fragment were musMT553F23 
(5′-GCCAGAGAACTACTAGCCATAGC-3′) and 
musMT668R23 (5′-AGCAAGAGATGGTGAGGTA-
GAGC-3′); primers for Kcnj13 (inward rectifier potassium 
channel 13) were mus4987F25 (5′-GGATGAGAGAGA-
GAAGCACAAGTGG-3′) and mus5140R25 (5′-CTGTAT-
GACCAACCTTGGACATGAT-3′). The primer pairs for 
KCNJ10 and Kcnj13 were used to amplify single nuclear 
reference genes. All primer pairs were optimized and 
checked by PAGE. The qPCRs were performed under the 
following conditions for the human/murine samples: 95 °C 
for 7:00 min, 45 cycles of 95 °C for 15 s and 62.5/62.6 °C 
(nuc gene) or 62.5/64.6 °C (mito gene) for 1 min, 95 °C for 
1 min and 55 °C for 1 min.
The obtained qPCR fluorescence data were analyzed by 
SigmaPlot (2001 for Windows version 7.0, Systat Software 
GmbH) and fitted with the Chapman sigmoidal regres-
sion curve [82]. Four parameters, i.e., y0, a, b and c, are 
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determining the shape of the sigmoidal regression curve 
and the degree of exponential function. These parameters 
were provided by the software from the equation y = y0 
+ a(1 − e−bx)c. The Ct value is calculated at the inflection 
point of the sigmoidal curve from the equation Ct = ln(c)/b.
The Ct values for the single nuclear reference genes 
KCNJ10 and Kcnj13 were used for calculation of the 
mtDNA copy number according to [83]. First, the cycle 
number difference (ΔCt) was calculated by subtracting the 
Ct values of the mtDNA fragment (Ctmito) of interest from 
the Ct values of the reference gene (Ctnuc), ΔCt = Ctnuc 
− Ctmito. Second, the copy number (CN) of the mtDNA 
relative to the diploid single nuclear gene was calculated as 
CN = 2 × 2ΔCt.
To validate the qPCR results, the PCR amplification effi-
ciency of each primer pair was determined as recommended 
(PCR efficiency = (10−1/slope − 1) × 100; [6]), which were 
97 % for MT3922F25/MT4036R26, 104 % for KIR835F19/
KIR903R19 (KCNJ10), 103 % for musMT553F23/
musMT668R23, and 95 % for mus4987F25/mus5140R25 
(Kcnj13). The calibration curves for each primer pair ampli-
fying DNA from human or murine control samples (serial 
dilution concentrations 3.2, 1.6, 0.16, 0.016 ng/µl) proved the 
excellent linearity of the qPCRs (data not shown). The NTC 
Ct values for each primer pair were as follows: 145/no curve/
no curve (negative values) for MT3922F25/MT4036R26, 
40.49/40.49/40.98 for KIR835F19/KIR903R19 (KCNJ10), 
40.8/97.7/50.4 for musMT553F23/musMT668R23, and 
40.09/43.95/38.99 for mus4987F25/mus5140R25 (Kcnj13).
Data analysis
Data analyses and statistical evaluations were performed 
using Excel 2010 (Microsoft); the Kruskal–Wallis one-way 
analysis of variance and the Mann–Whitney U (Wilcoxon 
rank-sum) statistical tests were done using the Excel add-
in “Real Statistics Resource Pack” version 3.1.2 by Charles 
Zaiontz available at http://www.real-statistics.com/. The 
number of independent experiments, number of technical 
replicates, mean values, standard errors, type of statistical 
test, and significance levels are indicated in the “Results” 
section or Figure legends. Final assembly and preparation 
of all figures for publication was done using Corel Draw 
Graphics Suite X7.
Results
Focal depletion of mitochondria in human and murine 
desminopathies
Human skeletal muscle specimens from a patient with a 
heterozygous R350P (c.1049G>C) desmin mutation [3] 
were analyzed by Gomori trichrome (not shown), COX, 
SDH, and desmin stains, respectively. Though no ragged-
red fibers or completely COX-negative/SDH-positive fibers 
were detected, multiple fibers displayed rubbed-out areas 
with attenuated or even absent COX and SDH enzymatic 
activities (Fig. 1a, left and middle panels, asterisks) indi-
cating focal depletion of mitochondria in multiple muscle 
fibers. To address the question whether the presence of 
desmin-positive protein aggregates correlates to sarcoplas-
mic areas with mitochondria depletion, we performed COX 
enzyme activity and desmin immunofluorescence stains 
on different serial transverse cryosections. Superimposed 
images indicated that the distribution of desmin protein 
aggregates is independent from the presence of mitochon-
drial rubbed-out lesions (Fig. 1a, right panel). Notably, this 
mitochondrial depletion pattern in the human desminopa-
thy was also detected in skeletal muscle of our homozygous 
R349P (c.1045_1047delAGG>insCCC) desmin knock-in 
mice (Fig. 1b, c, asterisks). In contrast, no obvious mito-
chondrial alterations were observed in heterozygous ani-
mals. The sections of murine soleus muscle used for these 
stains were derived from 3-month-old hetero- and homozy-
gous mice, which at this stage did not exhibit any signs of 
muscle weakness [16].
In a next step, we analyzed the subcellular distribution 
of mitochondria in cross-sections of murine soleus muscle 
of 3-month-old R349P desmin knock-in animals by indi-
rect immunofluorescence imaging. Compared to wild-type 
and heterozygous mice, COX IV immunostaining patterns 
in homozygous mice exhibited markedly reduced fluo-
rescence signal intensities in the intermyofibrillar space 
in the vast majority of fibers (Fig. 2a, asterisks), whereas 
the subsarcolemmal COX IV signal intensity remained 
unchanged. Furthermore, single fiber preparations 
from soleus muscles were used to study the relationship 
between the subcellular distribution of mitochondria and 
the desmin intermediate filament network. While fibers 
from heterozygous mice did not show any overt abnormal-
ities, fibers from homozygous mice displayed a marked 
disorder of the COX IV signal pattern with loss of its 
normal cross-striation arrangement (Fig. 2b). This altered 
organization was accompanied by a substantial change in 
the desmin staining pattern comprising a marked reduc-
tion of the overall signal intensity, an extensive loss of its 
cross-striation pattern, and the presence of subsarcolem-
mal and sarcoplasmic desmin-positive protein aggregates 
(Fig. 2b, arrowheads). In aged soleus muscle of 16-month-
old animals, the aberrant COX IV distribution was even 
more pronounced with multiple fibers displaying a virtu-
ally absent sarcoplasmic COX IV signal (Fig. 2c, aster-
isks). Herein, the R349P mutant desmin showed a partial 
co-localization with mitochondria in the subsarcolemmal 
region (Fig. 2c, arrowheads).
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Fig. 1  Focal depletion of mito-
chondria in skeletal muscles of 
a human R350P desminopathy 
patient and R349P desmin 
knock-in mice. a Cytochrome 
C oxidase (COX, brown) and 
succinate dehydrogenase (SDH, 
blue) double-stains of transverse 
and longitudinal cryosections 
from a German patient harbor-
ing the heterozygous R350P 
(c.1049G>C) desmin missense 
mutation [3]. Note the multiple 
rubbed-out areas (asterisks) 
devoid of COX and SDH 
enzyme activities demonstrating 
the absence of mitochondria. 
The right image represents 
a false color representation 
of two superimposed serial 
cryosections stained for COX 
(magenta) and desmin (black). 
Sarcoplasmic desmin-positive 
protein aggregates clearly 
display a distribution which is 
independent from the mitochon-
drial lesion pathology. b, c COX 
(b) and SDH (c) stains of trans-
verse and longitudinal cryosec-
tions from 3-month-old R349P 
(c.1045_1047delAGG>insCCC) 
desmin knock-in mice. Fibers 
of homozygote (HOM) animals 
display large and small areas 
of diminished enzyme stains 
(asterisks). Furthermore, muscle 
fibers in homozygote animals 
show an abnormal, thread-like 
distribution of mitochondria. 
Heterozygous (HET) mice 
showed no overt pathology as 
compared to wild-type (WT) 
littermates
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Mitochondrial pathology at the ultrastructural level
In our electron microscopic analysis of skeletal muscle 
tissue from desminopathy patients, we discovered that in 
the case of the heterozygous c.735G>C desmin mutation 
that leads to the expression of two mutant desmin pro-
teins, E245D and D214_E245del [14], areas with a subsar-
colemmal accumulation of mitochondria (Fig. 3a, ma) did 
prominently localize in close association with pathological 
protein aggregates composed of granulofilamentous mate-
rial (Fig. 3a, gfm). Moreover, enlarged mitochondria in the 
subsarcolemmal and intermyofibrillar regions were present 
(Fig. 3a, arrowheads). To assess whether these mitochon-
drial abnormalities observed in human desminopathy mus-
cle are also present in our R349P desmin knock-in mice, 
corresponding electron microscopy analyses of aged het-
erozygous R349P desmin knock-in mice were performed, 
occasionally revealing abnormal fibers with remnants of 
degenerating myofibrils that were interspaced with an accu-
mulation of enlarged mitochondria (Fig. 3b, middle panels). 
In keeping with our light microscopy data, the mitochon-
drial changes-comprising areas with depletion or accumu-
lation of mitochondria were present in the vast majority of 
muscle fibers derived from 6 to 8-month-old homozygous 
R349P desmin knock-in mice (Fig. 3b, bottom panels). In 
addition, enlarged mitochondria were frequently observed 
(Fig. 3b, bottom panels, arrowheads).
Expression of R349P desmin impacts the mitochondrial 
proteome and the respiratory chain complex 
organization
In a next step, we assessed mitochondrial dysfunction 
on the biochemical level. Since no sufficient amounts of 
human desminopathy biopsy material were available, these 
experiments were limited to murine muscle tissue. Meas-
urements of citrate synthase activity—a standard marker 
for intact mitochondria content—revealed a reduction by 
79 % in soleus muscle tissue homogenates derived from 
homozygous R349P desmin knock-in mice as compared 
to wild-type lysates (Fig. 4a). Subsequently, we analyzed 
enzyme activities of respiratory chain complexes I (Fig. 4b) 
and IV (data not shown) in tissue homogenates, both nor-
malized to muscle weight and to the citrate synthase activ-
ity. However, these experiments showed no statistically sig-
nificant differences between the three genotypes analyzed.
To quantitate the presence of both mtDNA and nuclear 
DNA-encoded protein subunits of the mitochondrial com-
plexes I–V, we employed immunoblotting as well as a prot-
eomic approach. For immunoblotting, identical amounts of 
total protein extracts from soleus muscle tissue were ana-
lyzed using antibodies directed against individual, nuclear 
DNA-encoded subunits of complexes I–V (Fig. 4c). This 
analysis revealed marked alterations in complex I that was 
detected by an anti-serum recognizing multiple subunits of 
complex I [8], while no overt changes for the complexes 
II–V were noted (Fig. 4c).
To address complex I–V subunit composition in more 
detail including mtDNA-encoded proteins, we performed 
label-free quantitative mass spectrometry analyses based 
on identical amounts of total protein extracts derived from 
either whole soleus muscles or type I fibers from lower 
extremity muscles (Fig. S1). The soleus muscle, which is 
rich in type I fibers, was chosen because it was found to be 
more susceptible to damage by mutant desmin than mus-
cle groups containing predominantly type II fibers [16]. 
Though the soleus muscle is composed of a relatively high 
amount of mitochondria-rich type I fibers (approx. 50 %), it 
still contains a significant number of type II fibers. Thus, to 
obtain samples of pure type I fibers, they were collected by 
laser microdissection from lower extremity muscles. Our 
analyses revealed specific differences related to the method 
of sample preparation, the knock-in mouse genotype, the 
individual mitochondrial respiratory chain complex, and 
the mitochondrial or nuclear origin of the individual pro-
tein subunit. Since the yield of identified respiratory chain 
proteins was much higher in soleus muscle homogenates 
than in the collected type I fibers, the former data gives a 
more comprehensive insight into the aberrant mitochon-
drial proteome. The analysis of mtDNA-encoded proteins 
in heterozygous mice showed a marked reduction (mean 
fold change as compared to wild-type: 0.64) of their abun-
dance, whereas the levels of these proteins in homozygous 
mice mostly were unchanged (mean fold change: 0.97). 
In contrast, the vast majority of nuclear-encoded proteins 
from all five respiratory complexes was found to be mark-
edly down-regulated in both hetero- and homozygous geno-
types (mean fold changes: het, complex I, 0.68; hom, com-
plex I, 0.65; het, complex II, 0.52; hom, complex II, 0.75; 
het, complex III, 0.69; hom, complex III, 0.63; het, com-
plex IV, 0.62; hom, complex IV, 0.79; het, complex V, 0.66; 
hom, complex V, 0.70). Thus, the quantitative proteomic 
analysis clearly demonstrated a mean overall decrease of 
the mtDNA- and nuclear DNA-encoded respiratory chain 
proteins of 34 and 30 % in heterozygous and homozygous 
soleus muscles, respectively. In agreement with our immu-
noblotting results (Fig. 4c, right panel; and [16]), the quan-
titative mass spectrometry data showed that the R349P 
mutant desmin protein levels were markedly reduced to 10 
% in homozygous mice.
Beyond changes in the levels of single respiratory 
chain and oxidative phosphorylation complex proteins, 
we addressed putative alterations with respect to the sizes 
and amounts of mitochondrial protein complexes I–V by 
native gel electrophoresis in conjunction with Coomas-
sie Brilliant Blue staining, immunoblotting, and specific 
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complex activity stains. For this purpose, mitochondria 
were enriched from soleus muscle tissue specimens derived 
from 4-month as well as 16-month-old animals, and iden-
tical amounts of mitochondria were subjected to protein 
separation by blue native electrophoresis (BNE). Coomas-
sie Brilliant Blue stained BN gels already indicated a slight 
decrease in the amount of complex I both as free component 
and as part of the large supercomplex SL in homozygous 
soleus muscles of 4-month-old animals (Fig. 5a, left panel, 
asterisks). This impression was substantiated by immunob-
lotting of complex I, which depicted a far more pronounced 
decrease (Fig. 5a, middle panel, asterisks). To determine 
the composition and stoichiometry of the respiratory super-
complexes, bands from BN gels containing the complexes 
I, III2, IV, S0, S1 and SL were further analyzed by quantita-
tive mass spectrometry. This analysis revealed that the res-
piratory supercomplex S0 (apparent native mass 1378 kDa) 
is formed by complex I and a dimer of complex III, S1 
(apparent native mass 1590 kDa) by complex I, a dimer of 
complex III and complex IV, and SL (apparent native mass 
2284 kDa) by two complex I and a dimer of complex III. 
Multiplex immunoblotting with antibodies directed against 
subunits of all complexes additionally revealed decreased 
signal intensities for the individual complex III (Fig. 5a, 
right panel, asterisks). The respiratory supercomplexes S0 
and S1 were present in comparable amounts in all three 
genotypes. When a similar analysis was performed using 
16-month-old desmin knock-in mice, decreased amounts 
of complexes SL, I, III, and IV in homozygous compared 
to wild-type soleus muscles were detected by Coomassie 
Brilliant Blue stained BN-PAGE gels as well as the corre-
sponding complex I and multiplex immunoblots (Fig. 5b, 
asterisks). Notably, in the aged heterozygous mice we addi-
tionally detected a decreased signal intensity of complex I 
as part of the supercomplex SL (Fig. 5b, middle and right 
panels, arrowheads). Furthermore, our gel-based complexes 
activity stains demonstrated that the decreased amounts of 
formed complexes I and SL (Fig. 5c, asterisks) are associ-
ated with a corresponding, lower enzyme activity.
Expression of mutant desmin leads to large‑scale 
mtDNA deletions and reduced mtDNA copy numbers
To address putative mtDNA damage, we performed long-
range PCRs using DNA extracted from skeletal muscles 
derived from three human desminopathy patients as well 
as from 6-month-old wild-type, heterozygous and homozy-
gous littermates of our R349P desmin knock-in mice. In all 
three human specimens, these PCR experiments resulted 
in the amplification of the full-length mtDNA (Fig. 6a). 
The samples of two out of the three desminopathy patients 
revealed the additional presence of large-scale mtDNA 
deletions. These deletions were observed in one previously 
reported patient harboring the heterozygous E245D/D214_
E245del (c.735G>C) desmin mutation (Fig. 6a, fourth col-
umn), who underwent muscle biopsy at the age of 38 years 
[14], and a second patient with a R350P (c.1049G>C) 
desmin mutation. Here, it is noteworthy that the R350P 
patient with the large-scale mtDNA deletions (father; 
52 years of age at biopsy; Fig. 6a, third column, with aster-
isk) and the one without large-scale mtDNA deletions (son; 
28 years of age at biopsy; Fig. 6a, second column) are 
members of the same previously reported family [3].
PCR analyses of wild-type mice resulted in the ampli-
fication of the full-length mtDNA, however, additional 
mtDNA species with large-scale deletions of different sizes 
were detected (Fig. 6b). A similar pattern was observed in 
heterozygous mice, which also showed these additional, 
rearranged mtDNA species. In contrast, the analysis of 
homozygous animals showed a clearly different picture, 
with only traces of the amplified full-length mtDNA in con-
junction with prominent signals corresponding to smaller 
mtDNA species (Fig. 6b). For quantitative evaluation of 
the mtDNA deletions, two different single molecule PCR 
(smPCR) series were performed using a first primer pair 
amplifying almost the entire mtDNA and a second primer 
pair amplifying a shorter region within the minor arc. 
The latter region of the mtDNA usually does not contain 
deletions and was used to determine the total amount of 
mtDNA molecules. For each genotype, the amount of large-
scale mtDNA deletions was calculated according to [83] by 
dividing the quotient of the number of positive bands to its 
single molecule dilution in the deletion PCR with the quo-
tient of the number of positive bands to its single molecule 
dilution in the total mtDNA amount PCR. This quantita-
tion demonstrated a tenfold increased amount of large-scale 
mtDNA deletion species in homozygous mice as compared 
to both wild-type and heterozygous littermates (Fig. 6b, 
inset). In principle, the mtDNA pathology in homozygous 
Fig. 2  Aberrant subcellular distribution of mitochondria and desmin 
intermediate filament pathology in R349P desmin knock-in mice. a 
Indirect immunofluorescence analysis of COX IV in transverse sec-
tions of 3-month-old soleus muscle from wild-type (WT), heterozy-
gous (HET) and homozygous (HOM) animals. Note the markedly 
reduced sarcoplasmic COX IV signal in multiple homozygous fibers 
(asterisks). b COX IV and desmin double-immunostains of isolated 
soleus muscle fibers. In contrast to a regular cross-striated staining 
pattern of both COX IV and desmin in wild-type and heterozygous 
R349P desmin knock-in mice, fibers from homozygous animals dis-
played a severe derangement of the mitochondria distribution, mark-
edly reduced overall desmin signal intensities, and the presence of 
small subsarcolemmal and sarcoplasmic desmin protein aggregates 
(arrowheads). c COX IV and desmin double-immunostains of trans-
verse sections of soleus muscle from 16-month-old homozygous 
mice. Note the presence of multiple fibers with virtual absence of 
the sarcoplasmic COX IV signal (asterisks) and the partial co-local-
ization of mitochondria and mutant desmin in the subsarcolemmal 
region (arrowheads)
◂
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R349P desmin knock-in mice may either be attributed to 
the presence of point-mutated desmin, the lack of wild-
type desmin, or both. To address this issue, we addition-
ally included age-matched, 6-month-old desmin knock-out 
mice [40] (for review see [15]) at this stage of analysis. 
Here, we found neither mtDNA deletions in wild-type nor 
in heterozygous mice, while homozygous desmin knock-
out mice were found to display some mtDNA deletions 
(Fig. 6c). The degree of mtDNA deletions, however, was 
remarkably lower as compared to the homozygous R349P 
desmin knock-in mice, in which the shortened mtDNA 
bands were the most prominent mtDNA species (Fig. 6b). 
Fig. 3  Electron microscopic visualization of mitochondrial pathol-
ogy in human and murine desminopathies. a Granulofilamentous 
material (gfm), subsarcolemmal accumulation of mitochondria (ma), 
and multiple enlarged mitochondria (arrowheads) in skeletal mus-
cle tissue from a German patient harboring a heterozygous E245D/
D214_E245del (c.735G>C) desmin mutation [14]. b Upper panel 
normal mitochondria regularly positioned adjacent to myofibrillar 
Z-discs in murine wild-type (WT) soleus muscle. Middle panel aged 
heterozygous (HET) R349P desmin knock-in mice occasionally dis-
played focal accumulation (ma) of normal and enlarged mitochon-
dria. Lower panel homozygous (HOM) mice, the left image illustrates 
the depletion of mitochondria in a large sarcoplasmic area comprising 
normal myofibrils and myofibrillar remnants. The right image depicts 
focal mitochondrial accumulation (ma) and enlarged mitochondria 
(arrowheads) in the intermyofibrillar space
◂
Fig. 4  Citrate synthase and complex I activities and expression lev-
els of single subunit proteins of respiratory complexes I–V in R349P 
desmin knock-in mice. a Determination of the citrate synthase activ-
ity by a spectrophotometric assay using identical amounts of total 
protein extracts. Note the marked activity reduction in homozygous 
mice. For this approach, soleus muscles obtained from five mice of 
each genotype (WT, HET, HOM) were pooled and subjected to four-
time repeated measurements. Column chart shows mean values of 
these technical replicates. b Determination of complex I activity by 
a colorimetric assay normalized to muscle weight. Though this analy-
sis, performed in duplicate on non-pooled samples derived from three 
animals per genotype, showed a reduction of complex I activity in 
homozygous mice, the data failed to reach statistical significance. 
An additional normalization of the obtained complex I values to the 
citrate synthase values resulted in similar activity levels for the three 
genotypes (data not shown). Column chart shows mean values and 
standard errors. c Immunoblotting using antibodies directed against 
specific complex I–V proteins revealed increased, decreased, and 
missing signals of complex I subunit proteins in heterozygous and 
homozygous mice, whereas the signal intensities of complex II–V 
subunit proteins showed no obvious differences. Desmin immuno-
blotting confirmed a markedly decreased level of mutant desmin in 
homozygous mice. In heterozygous mice the obtained signal is com-
posed of the signals from both R349 wild-type and P349 mutant 
desmin, as previously demonstrated by high resolution SDS-PAGE 
and immunoblotting [16]. GAPDH immunoblotting and Coomassie 
stained SDS-PAGE gels were used as loading controls
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Lastly, we studied the mtDNA copy numbers in the same 
skeletal muscle tissue specimens derived from the human 
desminopathy patients as well as the R349P desmin knock-
in and desmin knock-out mice. A marked reduction of the 
mtDNA copy number was observed in the aged R350P 
desminopathy patient with the multiple mtDNA deletions 
(Fig. 6d), and in homozygous desmin knock-in (Fig. 6e) 
and homozygous desmin knock-out mice (Fig. 6f).
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Discussion
Mitochondrial dysfunction has been described in a wide 
variety of human degenerative diseases affecting the cen-
tral nervous system [4, 5, 17, 36, 43, 52, 61, 72] and stri-
ated muscle tissue [35, 57]. In the context of myofibrillar 
myopathies, mitochondrial pathology has been reported in 
patients with mutations in filamin-C [34, 37, 46], myoti-
lin [34, 59], ZASP [34], FHL1 [48], plectin [69, 77], and 
desmin [3, 67, 68]. However, the functional relationship 
between the expression of a mutant, disease-causing pro-
tein and the associated mitochondrial dysfunction remains 
largely enigmatic in the majority of these disease entities.
A strong link for desminopathy and mitochondrial 
pathology
In the context of desminopathies, a direct functional link 
between desmin pathology and mitochondrial dysfunction 
can be formulated based on the observations that mitochon-
dria co-localize with the desmin intermediate filament net-
work [63] and that desmin knock-out mice display defects 
in the morphology and positioning as well as in the res-
piratory enzyme function of mitochondria in striated mus-
cle tissue [25, 44, 54]. However, the consequence of the 
expression of mutant desmin proteins on mitochondria is 
still an unresolved issue. To address this issue in a mecha-
nistic perspective, we analyzed skeletal muscle tissue spec-
imens derived from the R349P desmin knock-in mice and 
human desminopathy patients harboring heterozygous DES 
mutations.
In a first step, we compared SDH and COX stains 
of skeletal muscle from a human R350P (c.1049G>C) 
desminopathy patient with those from heterozygous and 
homozygous mice that carry the orthologous R349P 
(c.1045_1047delAGG>insCCC) desmin mutation. In the 
human biopsy, multiple fibers with large sarcoplasmic areas 
devoid of SDH and COX enzyme activities (“rubbed-out” 
lesions) were noted. However, COX-negative and ragged-
red fibers, which were previously reported to occur in spo-
radic and familial desminopathies [32, 50], were not found 
in our analysis. Evidence for mitochondrial abnormali-
ties comprising large and small areas of diminished COX 
and SDH enzyme stains were also present in the homozy-
gous R349P desmin knock-in mice, which solely express 
the mutant desmin. In addition, our immunofluorescence 
analysis of soleus muscle tissue and isolated fibers showed 
a reduced sarcoplasmic COX IV signal intensity. The 
ultrastructural analysis of human E245D/D214_E245del 
(c.735G>C) desminopathy muscle provided additional signs 
of mitochondrial pathology with accumulated and enlarged 
mitochondria. In line with our histochemistry results, our 
ultrastructural analysis of homozygous mice depicted areas 
with depletion or accumulation of mitochondria as well as 
enlarged mitochondria. Mitochondria with paracrystalline 
inclusions, which have been demonstrated in a previous 
report on human desminopathies [75], could not be detected.
Mitochondrial biochemistry in desminopathy
In a recent study, the analysis of citrate synthase-normal-
ized respiratory chain enzyme activities in skeletal mus-
cle homogenates of a heterozygous R350P desminopa-
thy patient, who was not related to both R350P desmin 
patients included in this study, gave normal results [34]. 
In our previous analysis of a desminopathy patient har-
boring a heterozygous single codon deletion (K240del; 
c.720_722delGAA), the analysis of respiratory chain 
enzymes in skeletal muscle homogenates also showed nor-
mal absolute and citrate synthase-normalized activities of 
complexes I and IV, but the analysis of single saponin-per-
meabilized skeletal muscle fibers finally depicted an in vivo 
inhibition of the complex I activity [67, 68]. However, in a 
patient with a heterozygous S13F (c.38C>T) desmin muta-
tion, more drastic mitochondrial enzyme activity changes 
including a significant reduction of the citrate synthase 
activity, an increase of complexes II to IV activities, and a 
loss of complex I activity were reported [50].
In line with the light and electron microscopy findings 
indicating a depletion of mitochondria, measurement of 
the citrate synthase activity revealed that it was strongly 
reduced in soleus muscle from homozygous R349P 
desmin knock-in mice. In contrast, neither complex I nor 
IV enzyme activities were significantly changed in hetero- 
and homozygous R349P desmin knock-in mice. Our mass 
spectrometry-based quantitation of nuclear and mtDNA-
encoded complex I–V protein subunits showed a marked 
reduction of their abundance in R349P desmin knock-in 
Fig. 5  Alterations of the respiratory chain and oxidative phospho-
rylation complex assembly as assessed by blue native gel electropho-
resis. Protein complexes derived from identical amounts of enriched 
mitochondria from 4- and 16-month-old wild-type (WT), heterozy-
gous (HET), and homozygous (HOM) R349P desmin knock-in lit-
termates were separated by blue native electrophoresis in 3–16 % 
acrylamide gradient gels. a, b Gels were Coomassie stained or used 
for immunoblotting against complex I subunits or “OXPHOS multi-
plex” using an antibody mix against all respiratory chain and oxida-
tive phosphorylation complexes. Note the reduced amounts of com-
plex I as free component and as part of the large supercomplex SL in 
young and aged homozygous mice (asterisks), and as part of super-
complex SL in aged heterozygous mice (arrowheads). c A native gel 
as in panel (a) was used for complex I activity visualization, which 
demonstrated a corresponding reduction of the enzymatic activity. 
Mitochondrial complexes are indicated: I, complex I; II, complex II; 
III, dimeric complex III; IV, complex IV; V, complex V; S0-1, respira-
tory supercomplexes containing complex I, dimeric complex III and 
0 to 1 copy of complex IV; SL, larger supercomplex containing two 
complex I and one complex III dimer
◂
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Fig. 6  Large-scale mtDNA deletions and reduced mtDNA copy 
numbers in human and murine desminopathies. a Total DNA 
extracted from human skeletal muscle specimens derived from a nor-
mal control (WT) and three different desminopathies was used for 
long-range PCRs to detect large-scale mtDNA deletions. Note the 
presence of large-scale mtDNA deletions visible as additional bands 
between 10 and 6 kbp in cases R350P* and E245D/D214_E245del. 
b Total DNA extracted from soleus muscles (same pooled material 
derived from five mice per genotype as used in Figs. 4a and S1) was 
used for five-times repeated long-range PCRs to detect large-scale 
mtDNA deletions in 6-month-old wild-type (WT), heterozygous 
(HET) and homozygous (HOM) R349P desmin knock-in mouse lit-
termates. Inset, amount of large-scale mtDNA deletions quantitated 
by a single molecule PCR (smPCR) approach. The numbers shown 
are mean values from three technical replicates using the pooled 
material from five mice per genotype. c Long-range PCRs from 
total DNA extracted from soleus muscles of 6-month-old wild-type 
(WT, three individual mice), heterozygous (HET, three individual 
mice) and homozygous (HOM, five individual mice) desmin knock-
out mouse littermates. While no large-scale mtDNA deletions were 
detected in wild-type and heterozygous mice, they were present 
in homozygous animals. Note, however, that the degree of mtDNA 
deletions was markedly lower as compared to homozygous R349P 
desmin knock-in mice, in which the shortened mtDNA bands were 
the most prominent species. d–f The mtDNA copy numbers (absolute 
values indicated inside the columns) were determined by quantitative 
real-time PCR in the human desminopathy (d), murine R349P desmin 
knock-in (e), and murine desmin knock-out (f) skeletal muscle speci-
mens as used in (a–c). Column charts indicate mean relative values 
from three technical replicates (d, e), and mean relative values and 
standard errors of the independent biological samples (f) with wild-
type values set as 1. A statistically significant difference between 
the three genotypes in (f) was first analyzed using the Kruskal–Wal-
lis one-way analysis of variance; post-hoc analyses were performed 
using the Mann–Whitney U test, and the single p value for the signifi-
cant difference between WT and HOM is indicated
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mice. The analysis of the respiratory chain and oxidative 
phosphorylation complexes by native gel electrophoresis 
demonstrated reduced amounts of assembled complexes I, 
III, and IV in homozygous mice. We additionally addressed 
the now widely accepted notion that complexes I, III and 
IV form stoichiometric and stable units called supercom-
plexes or respirasomes [65]. The formation of supercom-
plexes is thought to be essential for the stability of the 
individual complexes [1, 10, 21], efficient substrate chan-
neling [27], and for the prevention of reactive oxygen spe-
cies generation [49]. Our study provides also evidence for 
the formation of higher molecular complexes (SL), which 
are formed by higher organization of the respiratory super-
complexes into superassemblies [58, 79]. Notably, already 
young homozygous R349P desmin knock-in mice exhibited 
a reduced amount of complex I in the SL superassembly, 
whereas this deviation in the heterozygous state became 
only apparent in aged animals. This specific reduction of 
SL indicates that only the higher assembly of mitochondrial 
respiratory supercomplexes [71, 79] is destabilized by the 
presence of mutant desmin.
The state of mitochondrial DNA
Last but not least, we addressed the extent of the mtDNA 
damage in three human desminopathies and in our desmi-
nopathy mouse model. Long-range PCRs detected 
large-scale mtDNA deletions in one of the two R350P 
(c.1049G>C) desmin patients from the same family. 
Moreover, the E245D/D214_E245del (c.735G>C) desmi-
nopathy patient showed large-scale mtDNA deletions. In 
another, unrelated R350P desminopathy patient [34] and 
the aforementioned S13F (c.38C>T) desminopathy case 
with a documented loss of the complex I activity [50], no 
mtDNA deletions were detected. The S13F patient with-
out mtDNA deletions as well as our R350P patient with 
mtDNA deletions both displayed a markedly reduced 
number of mtDNA copies. The data derived from human 
desminopathy patients thus give a heterogeneous picture 
of the mtDNA pathology. Corresponding analyses in the 
R349P desmin knock-in mice demonstrated the presence 
of very prominent mtDNA deletion species and a mark-
edly reduced mtDNA copy number in homozygous mice. 
Though deletions of the mtDNA were also detected in 
wild-type animals, they were much more frequent in the 
heterozygous and homozygous conditions. Additionally, 
we performed analyses in age-matched desmin knock-out 
mice to distinguish effects due to the absence of desmin 
and the presence of point-mutated desmin. Though mtDNA 
deletions were detected in both homozygous R349P desmin 
knock-in and homozygous desmin knock-out mice, the 
former, which solely express mutant desmin at low abun-
dance, displayed much more pronounced alterations with 
very prominent shortened mtDNA species and almost no 
full-length mtDNA. The results in our three desminopathy 
models, i.e., heterozygous and homozygous desmin knock-
in and homozygous desmin knock-out mice, indicate that 
the expression of mutant desmin rather than the lack of 
desmin cause the mtDNA instability.
On the way to a pathomechanism
Our own data and the literature referenced here clearly 
demonstrate that the expression of mutant desmin affects 
mitochondria on different levels in skeletal muscle tissue. 
The most impressive effects were noted in homozygous 
R349P desmin knock-in mice, in which the sole expres-
sion of mutant desmin leads to a complete disruption of 
the desmin intermediate filament cytoskeleton. Though 
this lack of a filamentous system that provides topologi-
cal order may explain an aberrant subcellular distribution 
and consecutive damage of mitochondria, the substantial 
effects on mitochondrial size, abundance, distribution, 
enzyme activities, protein expression profiles, respiratory 
complex formation, and integrity of mtDNA strongly argue 
against a simple, concomitant secondary pathology. When 
translating our observations into the new concept of a mito-
chondrial network organization in skeletal muscle cells 
[20, 28] as derived by 3D-type visualization techniques, 
the absence of a functional desmin intermediate filament 
system will cause the reorganization of mitochondria into 
a less extended and ramified structure. The functional con-
sequences could be a less efficient metabolite exchange 
between mitochondria and sarcomeric units. Moreover, 
since affected mtDNA integrity was noted in homozygous 
R349P desmin knock-in, but only to a far lesser extent in 
desmin knock-out mice, it is tempting to speculate that the 
mutant desmin exerts an additional toxic gain of function 
on mitochondria.
Our biochemical analysis of the homozygous knock-in 
genotype also revealed a consistent defect of complex I 
itself and within respiratory supercomplexes. As demon-
strated in various neurodegenerative disorders, complex 
I seem to have an increased susceptibility to toxic protein 
species [26, 53, 70]. Since the observed mitochondrial 
pathology clearly preceded the clinical manifestation of 
muscle weakness in homozygous R349P desmin knock-in 
mice [16], we conclude that mutant desmin-induced mito-
chondrial dysfunction defines early disease stages, which 
significantly contribute to the progressive muscle dam-
age in autosomal-recessive desminopathies with main-
tained expression of mutant desmin. When we translate 
this assumption into the context of the more frequently 
occurring autosomal-dominant desminopathies, one has 
to keep in mind that the toxic effects of mutant desmin on 
the extrasarcomeric cytoskeleton [16] and mitochondria are 
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more focal in nature, due to the maintained expression of 
wild-type desmin from the non-mutated desmin allele and 
the observed segregation of mutant desmin from the wild-
type protein [16], which leads to the coexistence of mutant 
desmin aggregates and a desmin filament system.
With respect to gene-targeted mice as model systems for 
human disease, it is of interest to mention that our previ-
ous [16] and the present study revealed marked differences 
between human and murine heterozygous R350P/R349P 
desminopathies. Human patients usually develop progres-
sive and often devastating muscle weakness in their second 
to forth decade of life [15]. In contrast, our sedentary labo-
ratory mice, although they clearly display desmin-positive 
protein aggregation pathology and develop a cardiomyo-
pathy, do neither develop skeletal muscle weakness nor 
marked myopathological changes [16]. This difference sug-
gests that additional factors are needed to unveil the typical 
disease pathology in heterozygous R349P desmin knock-in 
mice. Accordingly, acute and strenuous physical exercise 
has recently been shown to markedly accentuate the muscle 
fiber pathology in heterozygous W2711X filamin-C knock-
in mice, which are a patient-mimicking model of filamin-C 
related myofibrillar myopathy [12]. Future exercise studies 
with the heterozygous R349P desmin knock-in mice will 
address the issue whether an acute energy demand acceler-
ates the general muscle pathology and increases the degree 
of mitochondrial pathology. These studies are clearly 
needed for further counselling of patients with regard 
to physical exercise as well as the development of novel 
therapeutic strategies modulating mitochondrial dysfunc-
tion, e.g., mitochondrial biogenesis or ROS production, 
in desminopathies and other forms of protein aggregate 
myopathies.
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